Withaferin A has also demonstrated anticancer activity against colon cancer by targeting and downregulating Notch-1 signaling via targets such as Hey-1 and Hes-1 and concurrently suppressing crosstalk between Notch-1 and Akt/mTOR pathways. This evidence concerns the gene NOTCH1 and colonic neoplasm.